Seres Therapeutics, Inc.
HealthcareNASDAQ:MCRB · NASDAQ Global Select
-$0.62 today
Vol 0.11M · Avg 0.05M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $5.7M +4088.2% | $136.0K +100.1% | -$113.7M +54.5% | -$250.2M -281.5% | -$65.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $4.1M -24.4% | $5.5M -12.4% | $6.2M -5.8% | $6.6M +11.5% | $5.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $10.8M -48.3% | $21.0M -38.5% | $34.1M +33.8% | $25.5M +26.0% | $20.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$27.8M +57.6% | -$65.5M -11.1% | -$59.0M -220.7% | -$18.4M -144.3% | $41.5M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $1.6M +175.0% | -$2.1M +76.2% | -$8.7M | $0 -100.0% | $9.4M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 +100.0% | -$33.8M -14.0% | -$29.6M | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$2.4M +18.5% | -$2.9M +74.6% | -$11.6M -625.6% | $2.2M -76.5% | $9.4M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$26.9M -0.9% | -$26.7M -194.2% | -$9.1M +55.9% | -$20.6M -190.4% | $22.8M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $8.2M +107.5% | -$109.7M -831.0% | $15.0M +96.9% | $7.6M +66.9% | $4.6M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $1.1M +100.8% | -$148.6M -26.6% | -$117.4M +48.7% | -$228.8M -3521.3% | $6.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$252.0K +33.7% | -$380.0K +95.2% | -$8.0M +18.8% | -$9.8M -2.7% | -$9.6M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $210.0K | $0 | $0 +100.0% | -$92.2M | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 -100.0% | $13.5M +405.4% | -$4.4M +90.8% | -$48.2M +49.8% | -$96.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 -100.0% | $142.7M +520.8% | $23.0M -83.6% | $140.5M -17.2% | $169.6M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 +100.0% | -$13.5M | $0 -100.0% | $92.2M | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$42.0K -100.0% | $142.3M +1244.7% | $10.6M -87.2% | $82.4M +28.6% | $64.1M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 +100.0% | -$127.9M -353.2% | $50.5M +96.6% | $25.7M +2810.9% | -$948.0K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $13.9M -40.9% | $23.5M +29.6% | $18.2M -82.1% | $101.2M | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $14.0M +362.5% | $3.0M +10.7% | $2.7M +28.6% | $2.1M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $13.9M +115.4% | -$90.4M -226.0% | $71.7M -44.7% | $129.6M +10901.9% | $1.2M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 +100.0% | -$1.0K -150.0% | $2.0K +300.0% | -$1.0K +0.0% | -$1.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $15.0M +115.5% | -$96.7M -175.7% | -$35.1M -108.9% | -$16.8M -123.3% | $72.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $865.0K +100.6% | -$149.0M -18.9% | -$125.3M +47.5% | -$238.6M -8191.8% | -$2.9M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Seer, Inc.
NASDAQ:SEER
$94.57M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Actuate Therapeutics Inc
ACTU
$48.33M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
Applied Therapeutics, Inc.
APLT
$14.86M
SEC Filings
Recent regulatory filings
No filings found.
Does MCRB generate free cash flow?
Seres Therapeutics, Inc. (MCRB) generated $865,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does MCRB produce?
Operating cash flow was $1.12M, before capital expenditures of $252,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.